Gossamer Bio, Inc. announced the appointment of Bob Smith as its Chief Commercial Officer. Mr. Smith has over 30 years of experience in pharmaceuticals, with a strong focus on PAH and rare disease. Since January 2023, Mr. Smith has been the National Sales Lead in charge of preparing for the potential launch of sotatercept for the treatment of PAH in the US at Merck & Co.

Prior to this, Mr. Smith was the President of LTM Pharma Consulting, where he helped build strategic brand, launch and organization plans for pre-commercial rare disease companies. Previously, until 2018, Mr. Smith was the Senior Vice President of Sales and Executive Leadership Team member at Actelion, where he spent more than eleven years in various senior commercial leadership roles. As the principal sales leader, Mr. Smith managed all U.S. sales operations, including sales, training, sales operations, patient & professional advocacy, key customer engagement and territory management.

Mr. Smith spearheaded two successful blockbuster PAH drug launches, OPSUMIT and UPTRAVI, which ultimately led to the purchase of Actelion by Johnson & Johnson in 2017 for $30 billion. Before joining Actelion, Mr. Smith held various pharmaceutical marketing and sales leadership roles, with a focus on cardiovascular franchises, at Nuvelo, Johnson & Johnson, and Bristol-Myers Squibb. Mr. Smith received a B.B.A. in Marketing from Texas A&M University.